Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

NCT06932068 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

77

Enrollment

OTHER

Sponsor class

Conditions

HER2 Negative
Low PD-L1 Expressing
Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)
DRUG: Oxallplation
DRUG: Capectitabine Tablets

Sponsor

Qilu Hospital of Shandong University